CervoMed Inc.: announces initial Phase 2a data for nfvPPA

What happened On Oct 12, 2026 CervoMed Inc announced initial data from the first 12 weeks of the Company’s Phase 2a clinical trial in nonfluent variant primary progressive aphasia (nfvPPA). The filing says these data were presented in a late-breaking oral presentation at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia, Pennsylvania.

The filing says the Company issued a press release on Oct 12, 2026 and attached it as Exhibit 99.1, which is incorporated by reference into the Form 8-K.

Key details

• Press release issued Oct 12, 2026 and attached as Exhibit 99.1.
• Initial data cover the first 12 weeks of the Phase 2a nfvPPA trial.
• Data were presented in a late-breaking oral presentation at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia.
• The filing reports Item 7.01 (Regulation FD disclosure) and Item 8.01 (other events).

Why it may matter This Form 8-K reports under Item 7.01, which covers Regulation FD disclosure of public information, and Item 8.01, which incorporates specified portions of the press release by reference. The filing does not show why the insider traded or why the company acted.